Modalis Therapeutics Corporation (4883.T)
JPY 103.0
(-1.9%)
JPY 103.0
(-1.9%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -2.25 Billion | -1.89 Billion | -747.46 Million | -376.57 Million | 224.14 Million |
| Net Income | -2.39 Billion | -2.7 Billion | -745.41 Million | -439.54 Million | 140 Million |
| Depreciation & Amortization | 731 Thousand | 123.67 Million | 77.87 Million | 57.58 Million | 6.69 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 9.63 Million | 10.73 Million | 5.76 Million | - | - |
| Change in working capital | 39.93 Million | 32.5 Million | 34.72 Million | -34.01 Million | 65.73 Million |
| Other non-cash items | 80.47 Million | -293.21 Million | -595.7 Million | 36.82 Million | -140 Million |
| Investing Cash Flow | -39.69 Million | -185.71 Million | 171.56 Million | -830.31 Million | -61.76 Million |
| Investments in PPE | -39.69 Million | -197.28 Million | -107.11 Million | -830.01 Million | -54.28 Million |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | - | 11.56 Million | -50.99 Million | -296 Thousand | -7.48 Million |
| Financing Cash Flow | 1.21 Billion | 63.68 Million | 72.63 Million | 2.77 Billion | 2.49 Billion |
| Debt repayment | -488.46 Million | - | - | - | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | -6.24 Million | - | -97 Thousand | - | - |
| Common Stock Issuance | 736.11 Million | 60.9 Million | 72.73 Million | 2.79 Billion | 2.49 Billion |
| Other Financing Activities | -8.13 Million | 2.77 Million | -1000.00 | -169 Thousand | -212 Thousand |
| Accounts receivables | -9.55 Million | 22.62 Million | -17.12 Million | 6 Million | -1.21 Million |
| Accounts payables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other working capital | 48 Million | -318 Million | -620 Million | 31 Million | 66.94 Million |
| Cash at beginning of period | 2.93 Billion | 4.93 Billion | 5.42 Billion | 3.85 Billion | 1.2 Billion |
| Cash at end of period | 1.88 Billion | 2.93 Billion | 4.93 Billion | 5.42 Billion | 3.85 Billion |
| Capital Expenditure | -39.69 Million | -197.28 Million | -107.11 Million | -830.01 Million | -54.28 Million |
| Effect of forex changes on cash | 27.98 Million | 14.77 Million | 17.98 Million | -6.86 Million | - |
| Net cash flow / Change in cash | -1.04 Billion | -2 Billion | -485.28 Million | 1.56 Billion | 2.65 Billion |
| Free Cash Flow | -2.29 Billion | -2.09 Billion | -854.57 Million | -1.2 Billion | 169.86 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -323 Million | -457 Million | -810 Million | -2.39 Billion | -548 Million | -501 Million |
| Depreciation & Amortization | - | - | - | 731 Thousand | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | 9.63 Million | - | - |
| Change in working capital | - | - | - | 39.93 Million | - | - |
| Other non-cash items | 323 Million | 457 Million | 810 Million | 80.47 Million | 548 Million | 501 Million |
| Investing Cash Flow | - | - | - | -39.69 Million | - | - |
| Investments in PPE | - | - | - | -39.69 Million | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | 1.21 Billion | - | - |
| Debt repayment | - | - | - | -488.46 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | -6.24 Million | - | - |
| Common Stock Issuance | - | - | - | 736.11 Million | - | - |
| Other Financing Activities | - | - | - | -8.13 Million | - | - |
| Accounts receivables | - | - | - | -9.55 Million | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | 48 Million | - | - |
| Cash at beginning of period | - | - | - | 2.93 Billion | - | - |
| Cash at end of period | - | - | - | 1.88 Billion | - | - |
| Capital Expenditure | - | - | - | -39.69 Million | - | - |
| Effect of forex changes on cash | - | - | - | 27.98 Million | - | - |
| Net cash flow / Change in cash | - | - | - | -1.04 Billion | - | - |
| Free Cash Flow | - | - | - | -2.29 Billion | - | - |
0821
MRTN
TITANSEC
TEXMOPIPES
SRPL
4725